AI drug rentosertib slows aging
Analysis based on 18 articles · First reported Sep 07, 2026 · Last updated Sep 08, 2026
The findings validate AI-driven drug discovery, potentially boosting investor interest in Insilico Medicine and similar biotech firms. However, the drug is years from approval, and the anti-aging effect requires confirmation in larger, dedicated trials, limiting immediate market impact.
Insilico Medicine, a China — Hong Kong-based biotech firm, published findings in Nature Biotechnology showing that its AI-designed drug rentosertib reduced biological age markers in patients with idiopathic pulmonary fibrosis (IPF). The drug, originally developed to treat IPF, was tested in a Phase 2a trial on 42-43 patients over 12 weeks. Reanalysis of blood samples using six proteomic aging clocks showed reductions in predicted biological age ranging from 2.6 to 6.2 years, with effects observed across all six clocks. Both the drug's molecular structure and its target protein TNIK were generated using AI. Experts caution that the trial was small, involved only IPF patients, and aging clocks remain debated. Further trials in healthy individuals are needed before regulatory approval.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard